Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma

A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL—short for trimeric APRIL (a proliferation-inducing ligand)—recognizes two proteins on myeloma cells instead of just one. Researchers…

Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

Uganda: Mbarara Hospital Raises Alarm Over Rising Cancer Cases, Late Patient Diagnosis

[Nile Post] Health specialists at Mbarara Regional Referral Hospital (MRRH) have raised concern over the growing cancer burden in southwestern Uganda, warning that late diagnosis and limited treatment…

  • Mbarara Hospital reports surge in cancer cases, with over 1,000 patients annually
  • Only 30% of patients receive confirmed diagnoses due to late presentation
  • Government plans to build Western Uganda Regional Cancer Centre to expand care

More from Wednesday 18 November →